TSTickerStar
Company alerts/EVMN
EVMN company alerts

EVMN updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for EVMN. Subscribe to EVMN alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Official-source feed

Recent EVMN alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

Investor eventInvestor relations

Evommune to Present at Evercore Healthcare Conference

Evommune, Inc. will present at the 9th Annual Evercore Healthcare Conference on December 2, 2026 at 10:25 am EST in Coral Gables, FL with a webcast available. Separately, the company announced that positive Phase 2a topline data for EVO301 in moderate-to-severe atopic dermatitis will be presented as a late-breaker oral session at the European Academy of Dermatology & Venereology Congress on October 1, 2026.

Read source-backed brief
SEC filingSEC filing

EVMN 10-Q filed 2026-11-12 | Key takeaways

EVMN filed its 10-Q; the most relevant disclosure change is added Subsequent events - Hinova license agreement: In November 2026, the company entered a license agreement with Hinova Pharmaceuticals Inc. for exclusive worldwide rights (excluding Greater China) to EVO570, an oral VAV1 molecular glue degrader, with $20.0M upfront cash payment, $10.0M in pre-funded warrants.

Read source-backed brief
Investor eventInvestor relations

Evommune to Participate in Stifel 2026 Healthcare Conference Fireside Chat

Evommune, Inc. will participate in a fireside chat at the Stifel 2026 Healthcare Conference on November 11, 2026 at 4:40 pm EST. The presentation will be webcast and is scheduled as a company participation at the investor conference. Supporting materials reference a recent Phase 2a data presentation for EVO301 in atopic dermatitis at the EADV Congress 2026 and corporate presentations on EVO570 and October 2026.

Read source-backed brief
Investor eventInvestor relations

EVO570: Potential Best-in-Class VAV1 Molecular Glue Degrader Webcast

Evommune, Inc. will host a webcast presentation on November 5, 2026 at 8:30am EST to present EVO570, a VAV1 molecular glue degrader. The presentation follows a late-breaker presentation of Phase 2a data for EVO301 in atopic dermatitis at the European Academy of Dermatology & Venereology Congress in Vienna, Austria. EVO570 is listed in the company's development pipeline alongside other inflammatory disease programs including IL-18BP fusion protein, MRGPRX2 antagonist, and TLR 7/8 antagonist.

Read source-backed brief
Debt offeringSEC filing

Evommune Announces $30 Million Common Stock Private Placement

Evommune entered into a securities purchase agreement to sell 4,966,889 shares of common stock at $6.04 per share to a select group of healthcare institutional investors, with anticipated gross proceeds of approximately $30 million before transaction-related expenses. The private placement is expected to close on or about November 6, 2026, subject to the satisfaction of customary closing conditions. Net proceeds are intended to advance clinical development programs, including EVO570, and for general corporate pu...

Read source-backed brief